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Design of small organic molecules via incorporation of two or
more ‘privileged scaffolds’ into a single molecular entity has
been a useful approach for identification of novel and efficient
ligands for various biological targets (Evans et al., 1988). Whileconsiderable efforts have been devoted on application of priv-
ileged structures in drug design and discovery (DeSimone
et al., 2004; Welsch et al., 2010) only a handful number of
reports are known on exploring the strategy of incorporating
two or more ‘privileged scaffolds’ in a single molecule. For
example, an indolyl-quinoxaline (Fig. 1) where two heterocy-
cles were connected through the indole N  1 nitrogen was
explored as a PAS kinase-inhibitor (McCall et al., 2011).
Notably, being present in a diverse range of drugs and natural
products with associated pharmacological activity indoles and
quinoxalines are considered as ‘privileged scaffolds’ and are
of significant importance in the drug development arena. This
encouraged us to focus on some novel indole-quinoxaline
hybrids to target phosphodiesterase 4 (PDE4).Journal
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Figure 1 Example of indolyl-quinoxaline as a PAS kinase-
inhibitor.
2 B.J. Luther et al.The enzyme phosphodiesterase 4 (PDE4), one of the 11
families of PDEs (PDE1-PDE11) has emerged as a promising
pharmacological target for the potential treatment of COPD
and asthma, a major public health burden worldwide. While
several selective PDE4 inhibitors (Kodimuthali et al., 2008)
have been developed as potential drugs including the recently
marketed roflumilast for the treatment of both COPD and
asthma, their launching has been delayed due to the undesired
side effects especially emesis (Spina, 2008; Rabe, 2011;
Lipworth, 2005). While the mechanisms for the side effects
observed with PDE4-selective inhibitors are not clearly under-
stood one of the approaches to overcome this problem is to
design, synthesize and evaluate new class of molecules for their
potential as PDE4 inhibitors. Though the use of strategy based
on hybrid molecule for the discovery of new drugs is notewor-
thy in the area of anticancer and antimalarial research
(Chauhan et al., 2010), its use is not common in the identifica-
tion of new PDE4 inhibitors. Nevertheless, the structural
features of an indole based potent PDE4 inhibitor (Gutke
et al., 2005; Draheim et al., 2004; Tralau-Stewart et al.,
2011) AWD-12-281 (Fig. 2) and our interest in quinoxaline
derivatives (Kumar et al., 2012a, 2012b; Nakhi et al., 2013a,
2013b; Babu et al., 2013; Sunke et al., 2014; Kolli et al.,
2014a, 2014b) prompted us to explore the strategy of hybrid
molecules for the identification of new PDE4 inhibitors. Thus
a new template A (Fig. 2) was designed by connecting the
indole moiety with the quinoxaline ring through a linker to
generate a library of hybrid molecules for testing against
PDE4. Herein, we report our preliminary results of this study.
Compounds represented by A (i.e. 6) were synthesized accord-
ing to the procedure shown in Scheme 1.
2. Materials and methods
2.1. General
Unless otherwise stated, reactions were performed under nitro-
gen atmosphere using oven dried glassware. Reactions were
monitored by thin layer chromatography (TLC) on silica gel
plates (60 F254), visualized with ultraviolet light or iodine
spray. Flash chromatography was performed on silica gel
(230–400 mesh) using distilled hexane, ethyl acetate, and
dichloromethane. NMR spectra were determined in CDCl3
solution by using a 400 MHz spectrometer. Proton chemical
shifts (d) are relative to tetramethylsilane (TMS, d= 0.00) as
internal standard and expressed in ppm. Spin multiplicities
are given as s (singlet), d (doublet), t (triplet) and m (multiplet)Please cite this article in press as: Luther, B.J. et al., Design and synthesis of novel ind
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.009as well as bm (broad multiplet). Coupling constants (J) are
given in hertz. Infrared spectra were recorded on a FT-IR
spectrometer. MS spectra were obtained on a mass spectrom-
eter (Agilent 6430 Triple Quadrupole LC/MS).
2.2. Synthesis of compound 4
A mixture of compound 3 (1.0 mmol), propargyl bromide
(1.5 mmol) and NaH (1.5 eq) in THF (5 mL) was stirred at
room temp for 2–4 h under a nitrogen atmosphere. After com-
pletion of the reaction (TLC), the mixture was poured into ice-
cold water (15 mL), stirred for 10 min and then extracted with
ethyl acetate (3  10 mL). The organic layers were collected,
combined, washed with cold water (2  10 mL), dried over
anhydrous Na2SO4, filtered and concentrated under low vac-
uum. The residue obtained was purified by column chromatog-
raphy on silica gel (230–400 mesh) using ethyl acetate/hexene
to give the desired product.
2.3. 3-Chloro-N-(4-chlorophenyl)-N-(prop-2-ynyl)quinoxalin-
2-amine (4a)
IR (KBr, cm1): 3275.3 („CAH), 2105.5 (AC„CA), 1541.6,
1490.3, 1362.3, 1225.9, 1073.2; 1H NMR (400 MHz, CDCl3) d:
7.94 (dd, J= 8.4, 0.9 Hz, 1H), 7.91 (dd, J= 8.3, 1.2 Hz, 1H),
7.73–7.68 (m, 1H), 7.62–7.57 (m, 1H), 7.36–7.31 (m, 2H), 7.09–
7.04 (m, 2H), 4.74 (d, J= 2.4 Hz, 2H, CH2), 2.21 (t,
J= 2.4 Hz, 1H, „CH); MS (ES mass): 328.0 (M+ 1).
2.4. 3-Chloro-N-(4-fluorophenyl)-N-(prop-2-ynyl)quinoxalin-
2-amine (4b)
IR (KBr, cm1): 3274.4 („CAH), 2108.3 (AC„CA), 1535.1,
1486.8, 1334.3, 1218.9, 1072.9; 1H NMR (400 MHz, CDCl3) d:
7.94 (d, J= 8.4 Hz, 1H), 7.90 (d, J= 8.0 Hz, 1H), 7.71–7.67
(m, 1H), 7.60–7.56 (m, 1H), 7.14–7.11 (m, 2H), 7.08–7.04 (m,
2H), 4.71 (d, J= 2.3 Hz, 2H, CH2), 2.21 (t, J= 2.3 Hz, 1H,
„CH); MS (ES mass): 311.8 (M+ 1).
2.5. Synthesis of compound 6
A mixture of compound 4 (1.2 mmol), 10% Pd/C (0.02 mmol),
PPh3 (0.15 mmol), CuI (0.03 mmol), and triethylamine
(2.40 mmol) in ethanol (5 mL) was stirred at 25–30 C for
30 min under nitrogen. To this was added o-iodoanilide (5)
(1.2 mmol), and the mixture was initially stirred at room tem-
perature for 1 h and then at 70 C for 6 h. After completion ofole-quinoxaline hybrids to target phosphodiesterase 4 (PDE4). Arabian Journal
Scheme 1 Synthesis of quinoxaline-indole based hybrid molecules 6.
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diluted with EtOAc (50 mL), and filtered through Celite. The
organic layers were collected, combined, washed with water
(3  30 mL), dried over anhydrous Na2SO4, filtered and con-
centrated under low vacuum. The crude residue was purified
by column chromatography on silica gel using methanol/
dichloromethane to afford the desired product.
2.6. 3-Chloro-N-(4-chlorophenyl)-N-((1-(methylsulfonyl)-1H-
indol-2-yl)methyl)quinoxalin-2-amine (6a)
1H NMR (400 MHz, CDCl3) d 8.04 (d, J= 8.2 Hz, 1H, C-8
quinoxalinyl H), 7.95 (d, J= 7.8 Hz, 1H, C-5 quinoxalinyl
H), 7.77 (d, J= 8.3 Hz, 1H, C-7 indolyl H), 7.68–7.67
(m, 1H, quinoxalinyl H), 7.63–7.62 (m, 1H, quinoxalinyl H),
7.48 (d, J= 7.6 Hz, 1H, C-4 indolyl H), 7.37–7.29 (m, 2H,
C-5 & C-6 indolyl H), 7.27 (d, J= 8.6 Hz, 2H, ArH), 7.02
(d, J= 8.6 Hz, 2H, ArH), 6.79 (s, 1H, C-3 indolyl H), 5.66
(s, 2H, CH2), 3.29 (s, 3H, MeSO2);
13C NMR (100 MHz,
CDCl3) d ppm 148.9 (C-2 quinoxalinyl), 145.6 (C-1
4-chlorophenyl), 142.2 (C-3 quinoxalinyl), 139.7 (C-2 indolyl),
138.9, 137.7, 137.0, 130.6, 130.5, 129.6 (2C), 129.1, 128.2,
127.8, 126.7, 124.6, 124.0 (2C), 123.8, 120.8, 113.8, 109.9
(C-3 indolyl), 51.9 (ACH2A), 40.9 (CH3SO2-); MS (ES mass):
497.1 (M+ 1); HPLC: 97.2%, column: X Terra C-18
250  4.6 mm 5 lm, mobile phase A: 5% ammonium acetate
in water, mobile phase B: CH3CN, gradient (T/%B): 0/20,
3/20, 12/95, 23/95, 25/20, 30/20; flow rate: 1.0 mL/min; UV
210 nm.
2.7. 3-Chloro-N-(4-chlorophenyl)-N-((5-methyl-1-
(methylsulfonyl)-1H-indol-2-yl)methyl)quinoxalin-2-amine
(6b)
1H NMR (400 MHz, CDCl3) d 7.89–7.87 (m, 2H), 7.72 (d,
J= 8.6 Hz, 1H), 7.67–7.63 (m, 1H), 7.60–7.55 (m, 1H), 7.59
(m, 1H), 7.27 (d, J= 8.6 Hz, 2H), 7.02 (d, J= 8.6 Hz, 2H),
7.14–7.09 (m, 1H), 6.68 (s, 1H, C-3 indolyl H), 5.57 (s, 2H,
CH2), 3.29 (s, 3H, MeSO2), 2.39 (s, 3H, CH3); MS (ES mass):
511.3 (M+ 1); HPLC: 97.6%, column: X Bridge C-18
150  4.6 mm 5 lm, mobile phase A: 0.1% HCOOH in water,
mobile phase B: CH3CN, gradient (T/%B): 0/40, 2/40, 9/98,
16/98, 17/40, 20/40; flow rate: 1.0 mL/min; UV 215 nm.Please cite this article in press as: Luther, B.J. et al., Design and synthesis of novel ind
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(methylsulfonyl)-1H-indol-2-yl)methyl)quinoxalin-2-amine
(6c)
1H NMR (400 MHz, CDCl3) d 7.88–7.86 (m, 1H), 7.71
(d, J= 8.6 Hz, 1H), 7.66–7.63 (m, 1H), 7.60–7.56 (m, 2H),
7.23 (s, 1H), 7.27 (d, J= 8.6 Hz, 2H), 7.13–7.08 (m, 1H),
7.02 (d, J= 8.6 Hz, 2H), 6.67 (s, 1H, C-3 indolyl H), 5.56
(s, 2H, CH2), 3.89 (s, 3H, OCH3), 3.24 (s, 3H, MeSO2); MS
(ES mass): 527.2 (M+ 1); HPLC: 96.8%, column: X
Bridge C-18 150  4.6 mm 5 lm, mobile phase A: 0.1%
HCOOH in water, mobile phase B: CH3CN, gradient (T/%
B): 0/40, 2/40, 9/98, 16/98, 17/40, 20/40; flow rate: 1.0 mL/
min; UV 215 nm.
2.9. 3-Chloro-N-(4-fluorophenyl)-N-((1-(methylsulfonyl)-1H-
indol-2-yl)methyl)quinoxalin-2-amine (6d)
1H NMR (400 MHz, CDCl3) d 7.92–7.90 (m, 1H), 7.79 (d,
J= 8.6 Hz, 1H), 7.75 (d, J= 8.3 Hz, 1H), 7.67–7.63 (m,
1H), 7.60–7.55 (m, 1H), 7.48 (d, J= 7.6 Hz, 1H), 7.37–7.29
(m, 2H), 7.06–6.98 (m, 4H), 6.78 (s, 1H, C-3 indolyl H), 5.62
(s, 2H, CH2), 3.24 (s, 3H, MeSO2); MS (ES mass): 480.9 (M
+ 1); HPLC: 96.9%, column: X Bridge C-18 150  4.6 mm
5 lm, mobile phase A: 0.1% HCOOH in water, mobile phase
B: CH3CN, gradient (T/%B): 0/40, 2/40, 9/98, 16/98, 17/40,
20/40; flow rate: 1.0 mL/min; UV 215 nm.
2.10. 3-Chloro-N-(4-fluorophenyl)-N-((5-methyl-1-
(methylsulfonyl)-1H-indol-2-yl)methyl)quinoxalin-2-amine
(6e)
1H NMR (400 MHz, CDCl3) d 7.89 (m, 2H, C-8 quinoxalinyl
H + C-7 indolyl H), 7.72 (d, J= 8.6 Hz, 1H, C-5 quinoxalinyl
H), 7.67–7.63 (m, 1H, quinoxalinyl H), 7.60–7.55 (m, 1H,
quinoxalinyl H), 7.24 (s, 1H, C-4 indolyl H), 7.14–7.09 (m,
1H, C-6 indolyl H), 7.07–6.99 (m, 4H, ArH), 6.68 (s, 1H, C-
3 indolyl H), 5.58 (s, 2H, CH2), 3.25 (s, 3H, MeSO2), 2.39 (s,
3H, Me); MS (ES mass): 494.8 (M+ 1); HPLC: 96.8%, col-
umn: X Bridge C-18 150  4.6 mm 5 lm, mobile phase A:
0.1% HCOOH in water, mobile phase B: CH3CN, gradient
(T/%B): 0/40, 2/40, 9/98, 16/98, 17/40, 20/40; flow rate:
1.0 mL/min; UV 215 nm.ole-quinoxaline hybrids to target phosphodiesterase 4 (PDE4). Arabian Journal
4 B.J. Luther et al.2.11. 3-Chloro-N-(4-fluorophenyl)-N-((5-methoxy-1-
(methylsulfonyl)-1H-indol-2-yl)methyl)quinoxalin-2-amine
(6f)
1H NMR (400 MHz, CDCl3) d 7.88–7.86 (m, 1H), 7.71 (d,
J= 8.6 Hz, 1H), 7.66–7.63 (m, 1H), 7.60–7.56 (m, 2H), 7.23
(s, 1H), 7.13–7.08 (m, 1H), 7.06–6.98 (m, 4H), 6.67 (s, 1H),
5.56 (s, 2H, CH2), 3.89 (s, 3H, OCH3), 3.24 (s, 3H); MS (ES
mass): 510.97 (M+ 1); HPLC: 98.1%, column: X Bridge
C-18 150  4.6 mm 5 lm, mobile phase A: 0.1% HCOOH in
water, mobile phase B: CH3CN, gradient (T/%B): 0/40, 2/40,
9/98, 16/98, 17/40, 20/40; flow rate: 1.0 mL/min; UV 215 nm.
2.12. 3-Chloro-N-(4-fluorophenyl)-N-((1-tosyl-1H-indol-2-yl)
methyl)quinoxalin-2-amine (6g)
1H NMR (400 MHz, CDCl3) d 8.03 (dd, J= 9.1, 4.2 Hz, 1H),
7.91 (d, J= 8.0 Hz, 1H), 7.76 (d, J= 8.3 Hz, 3H), 7.67 (m,
2H), 7.48 (d, J= 7.6 Hz, 1H), 7.37–7.29 (m, 2H), 7.24 (d,
J= 8.1 Hz, 2H), 7.04–6.95 (m, 4H), 6.74 (s, 1H), 5.68 (s,
2H), 2.39 (s, 3H); MS (ES mass): 557.02 (M+ 1); HPLC:
98.2%, column: X Bridge C-18 150  4.6 mm 5 lm, mobile
phase A: 0.1% HCOOH in water, mobile phase B: CH3CN,
gradient (T/%B): 0/40, 2/40, 9/98, 16/98, 17/40, 20/40; flow
rate: 1.0 mL/min; UV 215 nm.
2.13. 3-Chloro-N-((5-fluoro-1-tosyl-1H-indol-2-yl)methyl)-N-
(4-fluorophenyl)quinoxalin-2-amine (6h)
1H NMR (400 MHz, CDCl3) d 8.05 (dd, J= 9.1, 4.2 Hz, 1H,
C-8 quinoxalinyl H), 7.92 (d, J= 8.0 Hz, 1H, C-5 quinoxalinyl
H), 7.77 (d, J= 8.3 Hz, 2H, ArH), 7.67 (m, 2H, quinoxalinyl
H), 7.59 (m, 1H, C-4 indolyl H), 7.24 (d, J= 8.1 Hz, 2H,
ArH), 7.04–6.95 (m, 6H, ArH+ indolyl H), 6.64 (s, 1H, C-3
indolyl H), 5.76 (s, 2H, CH2), 2.39 (s, 3H, Me); MS (ES mass):
574.8 (M+ 1); HPLC: 97.5%, column: X Bridge C-18
150  4.6 mm 5 lm, mobile phase A: 0.1% HCOOH in water,
mobile phase B: CH3CN, gradient (T/%B): 0/40, 2/40, 9/98,
16/98, 17/40, 20/40; flow rate: 1.0 mL/min; UV 215 nm.
2.14. 3-Chloro-N-(4-fluorophenyl)-N-((5-methyl-1-tosyl-1H-
indol-2-yl)methyl)quinoxalin-2-amine (6i)
1H NMR (400 MHz, CDCl3) d 7.89–7.87 (m, 2H), 7.72 (d,
J= 8.6 Hz, 1H), 7.77 (d, J= 8.3 Hz, 2H), 7.67–7.63 (m,
1H), 7.60–7.55 (m, 1H), 7.59 (m, 1H), 7.24 (d, J= 8.1 Hz,
2H), 7.14–7.09 (m, 1H), 7.07–6.99 (m, 4H), 6.68 (s, 1H, C-3
indolyl H), 5.58 (s, 2H, CH2), 2.40 (s, 3H, CH3), 2.39 (s, 3H,
CH3); MS (ES mass): 571.09 (M+ 1); HPLC: 97.3%, column:
X Bridge C-18 150  4.6 mm 5 lm, mobile phase A: 0.1%
HCOOH in water, mobile phase B: CH3CN, gradient
(T/%B): 0/40, 2/40, 9/98, 16/98, 17/40, 20/40; flow rate:
1.0 mL/min; UV 215 nm.
2.15. Docking procedure
The PDE4B receptor in complex with Rolipram (PDB
code-1XMY) was used as the receptor for docking study.
The original PDB file contains crystallized Zn and Mg metal
ions. The PDE Proteins were retrieved from PDB andPlease cite this article in press as: Luther, B.J. et al., Design and synthesis of novel ind
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.009Protonated (addition of Hydrogen atoms) with Protonation
3D application in MOE, Connolly Molecular surface was
generated around the ligand site of the protein, and Gasteiger
Partial charges were added to the protein and finally energy
minimized to relieve bad crystallographic contacts. ‘‘Active site
finder” function of the MOE software was used to denote
potential docking pockets within the Protein crystal structure.
The test compounds were placed in the Active site pocket of
the protein by the ‘‘Triangle Matcher” method, which gener-
ated poses by aligning the ligand triplet of atoms with the tri-
plet of alpha spheres in cavities of tight atomic packing. Dock
scoring was carried out using the London dG method and then
retaining and scoring the best 10 poses of molecules finally.
The preparation of the ligands for Docking Simulation
involved the energy minimization with Molecular Mechanics
Force-field MMFF94 (Merck Molecular Force Field 94)
and then molecules were subjected to conformational search
in MOE using the Conformations Stochastic search module
to find the lowest energy conformers.
The docking results were appeared as Docking Score in
which the docking poses were ranked by the Molecular
Mechanics and Generalized Born solvation model (MM/
GBVI) binding free energy.
For all scoring functions, lower scores indicated more
favorable poses. The unit for all scoring functions is kcal/mol.
The final energy was calculated using the Generalized Born
solvation model. Poses for each ligand were scored based on
complementarity with the binding pocket.
The London dG scoring function estimated the free energy
of binding of the ligand from a given pose. The functional
form is a sum of terms:
DG ¼ cþ Eflex þ
X
h-bonds
cHBfHB þ
X
m-lig
cMfM þ
X
atoms i
DDi
where c represents the average gain/loss of rotational and
translational entropy; Eflex is the energy due to the loss of flex-
ibility of the ligand (calculated from ligand topology only);
fHB measures geometric imperfections of hydrogen bonds
and takes a value in [0,1]; cHB is the energy of an ideal hydro-
gen bond; fM measures geometric imperfections of metal liga-
tions and takes a value in [0,1]; cM is the energy of an ideal
metal ligation; and Di is the desolvation energy of atom i.
2.16. In vitro assay for PDE4B
2.16.1. Cells and reagents
Sf9 cells were obtained from ATCC (Washington, DC, USA)
and were routinely maintained in Grace’s supplemented med-
ium (Invitrogen) with 10% FBS. cAMP was purchased from
SISCO Research Laboratories (Mumbai, India). PDElight
HTS cAMP phosphodiesterase assay kit was procured from
Lonza (Basel, Switzerland). PDE4B1 clone was procured from
OriGene Technologies (Rockville, MD, USA). PDE4D2
enzyme was purchased from BPS Bioscience (San Diego,
CA, USA).
2.16.2. PDE4B protein production and purification
PDE4B1 cDNA was sub-cloned into pFAST Bac HTB vector
(Invitrogen) and transformed into DH10Bac (Invitrogen) com-
petent cells. Recombinant bacmids were tested for integration
by PCR analysis. Sf9 cells were transfected with bacmid usingole-quinoxaline hybrids to target phosphodiesterase 4 (PDE4). Arabian Journal
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instructions. Subsequently, P3 viral titer was amplified, cells
were infected and 48 h postinfection cells were lysed in lysis
buffer (50 mM Tris–HCl pH 8.5, 10 mM 2-Mercaptoethanol,
1% protease inhibitor cocktail (Roche), 1% NP40). Recombi-
nant His-tagged PDE4B protein was purified as previously
described elsewhere (Wang et al., 1997). Briefly, lysate was cen-
trifuged at 10,000 rpm for 10 min at 4 C and supernatant was
collected. Supernatant was mixed with Ni–NTA resin (GE Life
Sciences) in a ratio of 4:1 (v/v) and equilibrated with binding
buffer (20 mM Tris–HCl pH 8.0, 500 mM-KCl, 5 mM imida-
zole, 10 mM 2-mercaptoethanol and 10% glycerol) in a ratio
of 2:1 (v/v) and mixed gently on rotary shaker for 1 h at 4 
C. After incubation, lysate-Ni–NTA mixture was centrifuged
at 4500 rpm for 5 min at 4 C and the supernatant was col-
lected as the flow-through fraction. Resin was washed twice
with wash buffer (20 mM Tris–HCl pH 8.5, 1 M KCl,
10 mM 2-Mercaptoethanol and 10% glycerol). Protein was
eluted sequentially twice using elution buffers (Buffer I:
20 mM Tris–HCl pH 8.5, 100 mM KCl, 250 mM imidazole,
10 mM 2-mercaptoethanol, 10% glycerol, Buffer II: 20 mM
Tris–HCl pH 8.5, 100 mM KCl, 500 mM imidazole, 10 mM
2-mercaptoethanol, 10% glycerol). Eluates were collected in
four fractions and analyzed by SDS–PAGE. Eluates contain-
ing PDE4B protein were pooled and stored at 80 C in
50% glycerol until further use.
2.16.3. PDE4 enzymatic assay
The inhibition of PDE4 enzyme was measured using PDE light
HTS cAMP phosphodiesterase assay kit (Lonza) according to
manufacturer’s recommendations. Briefly, 10 ng of in house
purified PDE4B1 enzyme was pre-incubated either with
DMSO (vehicle control) or with compound for 15 min before
incubation with the substrate cAMP (5 lM) for 1 h. The reac-
tion was halted with stop solution and reaction mix was incu-
bated with detection reagent for 10 min in dark. Luminescence
values (RLUs) were measured by a Multilabel plate reader
(Perklin Elmer 1420 Multilabel counter). The percentage of
inhibition was calculated using the following formula:
%inhibition¼ðRLUof vehicle controlRLU of inhibitiorÞ
RLU of vehicle control
1003. Results and discussion
3.1. Docking studies
Before undertaking the actual chemical synthesis of the library
of hybrid molecules based on A, we performed in silico docking
studies (Card et al., 2004; Corbeil et al., 2012; Dym et al., 2002;
Oliveria et al., 2006; Gangwal et al., 2015; Franc¸a et al., 2013)
using a specific molecule B (Fig. 3) that belongs to A. We also
used the individual fragment of B e.g. C and D (Fig. 3) for the
docking studies to assess the usefulness of our concept in the
present case. It is known that the PDE4 enzyme has four
subtypes e.g. PDE4A, B, C, and D of which PDE4B is the
major subtype responsible for mediating LPS-induced
inflammation (Kodimuthali et al., 2008). Thus apart from
cyclooxygenase-2 inhibition (Ramalho et al., 2009), the inhibi-
tion of PDE4B has been hypothesized as the basis of effectivePlease cite this article in press as: Luther, B.J. et al., Design and synthesis of novel ind
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.009anti-inflammatory treatment and therefore this particular sub-
type was chosen as the target protein for both in silico and
in vitro studies. A well known PDE4 inhibitor rolipram
(Fig. 3) was used as a reference compound in these studies.
The molecular docking simulation studies were performed
using the Chemical Computing Group’s Molecular Operating
Environment (MOE) software 2008.10 Version, ‘‘DOCK”
application module. The PDE4B receptor in complex with roli-
pram (PDB code-1XMY) was used as the receptor for dock-
ing. To validate the docking accuracy of the program used,
the native co-crystallized rolipram ligand was docked back
into its binding site of PDE4B protein. The molecule B and
its two individual fragments C and D along with the reference
compound rolipram were docked into the PDE4B protein. The
docking studies mainly involved searching for favorable bind-
ing configurations of ligands in macromolecular target (i.e. the
PDE4B protein) and for each ligand, a number of configura-
tions called poses were generated and scored in an effort to
determine favorable binding modes. The results are summa-
rized in Table 1.
It is evident from Table 1 that the molecule B showed dock
score comparable with rolipram whereas dock score of its indi-
vidual fragments C and D was found to be inferior. In view of
the fact that dock score is the reflection of extent of binding of
a given molecule with the target protein, C and D appeared as
mediocre inhibitors of PDE4B in silico. However, their com-
bined form B was identified as a better and potential inhibitor
of PDE4B indicating usefulness of the concept. The docking
studies also demonstrated that these compounds utilized the
conserved binding site of the PDE4B protein whereby the
sulphonyl oxygen of the indole ring played a major role in
forming H-bond. In general, these compounds interacted
either with the conserved residues such as Tyr233 of Q pocket
(e.g. compounds C and D, see supporting info) or with His234
of metal binding pocket (e.g. compound B) in the active site of
PDE4B and most of them showed a common arene-arene
interaction with Phe446. The docking of compound B is shown
in Fig. 4. Notably, like B rolipram also formed H-bond with
His234 of PDE4B.
3.2. Chemistry
In view of the promising in silico results obtained for B
through docking studies we planned to synthesize molecules
based on A including B. A Pd/C-catalyzed coupling-
cyclization strategy leading to the formation of indole ring
was used to prepare our target molecules (Scheme 1) (Pal,
2009; Pal et al., 2004; Layek et al., 2009). We preferred this
strategy as the concerned methodology involved the use of less
expensive, stable, easy to handle and recyclable Pd/C which is
advantageous over the other Pd-based methodologies. More-
over, this strategy is known to allow the construction of appro-
priately substituted indole ring of our choice. The starting
alkyne (4) was prepared via propargylation of N-aryl substi-
tuted 3-chloroquinoxalin-2-amine (3) which in turn was pre-
pared via the reaction of 2,3-dichloroquinoxaline (1) with
anilines (2) in the presence of AlCl3 in 1,2-dichloroethane
(DCE) (Prasad et al., 2012). The terminal alkyne 4 thus
obtained was used for the coupling-cyclization with a range
of o-iodoanilides (5) in the presence of 10% Pd/C, PPh3, CuI
and Et3N in EtOH.ole-quinoxaline hybrids to target phosphodiesterase 4 (PDE4). Arabian Journal
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Figure 3 The specific molecule B, its two individual fragments C and D and the known PDE4 inhibitor rolipram.
Table 1 The dock score and summary of molecular interac-
tions of top-ranked docking poses of B, C and D along with
rolipram.
MOE Dock score (kcal/mol) H-bond interactions
Compounds PDE4B PDE4B
Rolipram 24.61 His234, Gln443
B 21.54 His 234
C 15.29 Tyr233
D 16.36 Tyr233
6 B.J. Luther et al.The optimized reaction condition for the synthesis of 6 was
established by reacting the alkyne 4a (Ar = C6H4Cl-p) with
N-(2-iodophenyl)methanesulfonamide (5a) in the presence of
10%Pd/C–PPh3-CuI as a catalyst system under various condi-
tions (Table 2). The reaction afforded the expected product 6a
in 43% yield when performed in MeOH at 60 C for 4 h (entry
1, Table 2). However, the product yield was increased to 78%Figure 4 Docking of compound B
Please cite this article in press as: Luther, B.J. et al., Design and synthesis of novel ind
of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.08.009when the reaction was carried out in EtOH at 70 C (entry 2,
Table 2). We then assessed the role of catalyst, co-catalyst,
ligand and base in the present reaction. The reaction afforded
either poor yield of product 6a or no product when performed
in the absence of Pd/C (entry 3, Table 2), or CuI (entry 4,
Table 2) or PPh3 (entry 5, Table 2). All these reactions were
performed using Et3N as a base. However, the use of K2CO3
in place of Et3N (entry 6, Table 2) was found to be less effec-
tive. A side reaction perhaps due to the reaction of 4a with
EtOH in the presence of K2CO3 was observed in this case.
Thus the condition of entry 2 of Table 2 was used for the gen-
eration of a small library of molecules based on A (Chart 1). It
is evident from Chart 1 that reactions proceeded well in all the
cases to afford the desired product 6a-i in good to acceptable
yields. Compounds containing N-mesyl indole e.g. 6a-f and
N-tosyl indole moiety e.g. 6g-i were synthesized conveniently
using this strategy. It is worthy to mention that while chloro
group of 3-chloroquinoxalin-2-amines is known to participate
in the Pd/CACu mediated alkynylation reaction (Prasad et al.,into PDE4B (PDB code-1XMY).
ole-quinoxaline hybrids to target phosphodiesterase 4 (PDE4). Arabian Journal
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Chart 1 The list of quinoxaline-indole based hybrid molecules 6 prepared via Pd/CACu catalyzed coupling-cyclization strategy
(Scheme 1). (All the reactions were carried out using alkyne 4 (1 equiv.), 5 (1 equiv.), 10% Pd/C (0.016 equiv.), PPh3 (0.125 equiv.), CuI
(0.02 equiv.), and Et3N (2 equiv.) in EtOH at 70 C for 4 h. Figures within the bracket indicate isolated yields.)
Table 2 Effect of reaction conditions on coupling of terminal alkyne 4a with o-iodoanilide 5a.a
N
N
N
Cl
4a
Cl I
NHSO2Me
5a
+
N
N Cl
N
N
S
O Me
O
6a
Cl
Pd-cat
CuI
Solvent
Base
Entry Catalyst Solvent/base Temp (C)/time (h) % yieldb
1 10%Pd/C-PPh3 MeOH/Et3N 60/4 43
2 10%Pd/C-PPh3 EtOH/Et3N 70/4 78
3 PPh3 EtOH/Et3N 70/12 17
c
4 10%Pd/C-PPh3 EtOH/Et3N 70/12 No product
d
5 10%Pd/C EtOH/Et3N 70/12 10
e
6 10%Pd/C-PPh3 EtOH/K2CO3 70/4 21
a All reactions were carried out using 5a (1 equiv.), alkyne 4 (1 equiv.), a Pd-catalyst (0.016 equiv.), PPh3 (0.125 equiv.), CuI (0.02 equiv.), and
a base (2 equiv.) in EtOH (5.0 mL), at 70 C.
b Isolated yield.
c The reaction was carried out without Pd/C.
d The reaction was carried out without CuI.
e The reaction was carried out without PPh3.
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Figure 5 Selected 1H and 13C signals shown by compound 6a.
8 B.J. Luther et al.2012), the chloro group of 4 remained inert in the present reac-
tion perhaps due to the higher reactivity of iodo group of 5
toward the Pd catalyst. Thus, the active Pd(0) species
generated in situ (Pal, 2009; Pal et al., 2004; Layek et al.,
2009) (Scheme 2) undergoes oxidative addition with 5 rather
than 4 to give the organo-Pd(II) species E-1 which on
transorganometallation with copper acetylide generated
in situ from CuI and 4 affords E-2. The reductive elimination
of Pd(0) from E-2 affords the internal alkyne E-3 which subse-
quently undergoes Cu-mediated intramolecular ring closure to
give the desired product 6 via E-4. Thus the whole process
seemed to proceed via two catalytic cycles i.e. the Pd-cycle
followed by a Cu-cycle.
All the quinoxaline-indole based hybrid molecules 6
prepared were characterized by spectral data and the selected
1H and 13C signals of a representative compound 6a are shown
in Fig. 5. Thus appearance of peaks at d 6.79, 5.66 and
3.29 ppm in 1HNMR spectra of 6a was due to the C-3 indolyl
proton, methylene group at C-2 of the indole ring and methyl
group of mesyl moiety. The 13C signals of compound 6a
observed at 148.9 and 142.2 ppm were due to the C-2 and
C-3 carbon of the quinoxaline ring, and the signals at 139.7
and 109.9 ppm were due to the C-2 and C-3 carbon of indole
ring. The other signals appeared at 145.6 ppm were due to
the C-1 carbon of the 4-chlorophenyl ring, at 51.9 ppm were
due to the methylene carbon and at 40.9 ppm were due to
the mesyl carbon.4
N
N Cl
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O R
O Z
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Scheme 2 Proposed reaction mechanism for the Pd/CACu mediate
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All the synthesized compounds were evaluated for their PDE4
inhibitory potential in vitro (Wang et al., 1997). While most of
the compounds showed mediocre to good inhibition of PDE4B
when tested at 30 lM the most notable were identified as 6a
(56% inhibition), 6e (61%), 6g (67%), 6h (79%) and 6i
(64%). These compounds showed > 50% inhibition of PDE4B
except 6h that showed 79% inhibition. The reference com-
pound rolipram showed 90% inhibition at 10 lM in the same
assay. While the docking of 6a and 6e into PDE4B showed
good interactions with this protein (see supporting info) their
dock score (19.34 kcal/mol for 6a and 19.70 kcal/mol for
6e) indicated that 6h (dock score 21.54 kcal/mol) interactedN
N N
Cl
Ar
Cu
N
N
N
Cl
Ar
Pd
RO2SN
N
N
N
Cl
Ar
RO2SNE-3
E-2
BH I
3N)
II
cle
+ CuI
BH
BH
uI
d coupling-cyclization 5 with 4 leading to the desired product 6.
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Table 3 Inhibition of PDE4B by compound 6h and rolipram.
Compounds % inhibition of PDE4Ba
30 lM 10 lM 5 lM 1 lM 0.1 lM
6h 79 63 48 31 ND
Rolipram ND 90 73 53 32
ND= not determined.
a Average of three determinations.
Design and synthesis of novel indole-quinoxaline hybrids 9better. This is in agreement with the observed superior in vitro
activities of compound 6h (79% inhibition) compared to 6a
(56% inhibition) and 6e (61% inhibition). Moreover,
compounds C [prepared via AlCl3 mediated reaction of 1 with
N-ethyl-4-fluoroaniline (cf first step of Scheme 1)] and D
(prepared via the reaction of 5-fluoroindole and p-tosyl chlo-
ride) were tested for their PDE4 inhibitory potential in vitro.
As predicted earlier, both of these compounds (<50% inhibi-
tion at 30 lM) were found to be inferior compared to 6h (i.e.
B, Fig. 3). Overall, based on in vitro data theN-(p-tosyl) deriva-
tives (6g–i) in general were identified as better inhibitors than
the N-mesyl derivatives (6a–f). Among the N-(p-tosyl) deriva-
tives, the presence of fluorine at C-5 position of the indole ring
(e.g. 6h) was beneficial over a hydrogen (e.g. 6g) or methyl sub-
stituent (e.g. 6i) at the same position. To assess the potential of
compound 6h further this compound was tested at different
concentrations and the % inhibition observed is summarized
in Table 3. The compound 6h showed consistent dose-
dependent inhibition of PDE4B across all the concentration
tested and its IC50 was calculated as 5.11 ± 0.24 lM. More-
over, this compound showed some selectivity toward PDE4B
over PDE4D (e.g. 79% inhibition of PDE4B vs 41% inhibition
of PDE4D at 30 lM). Thus the compound 6h was identified as
a PDE4 inhibitor of further interest.
4. Conclusions
In conclusion, the concept of hybrid molecules has been
explored as a new strategy to identify novel inhibitors of
PDE4. Thus, a series of hybrid molecules were designed ration-
ally by connecting an indole moiety with a quinoxaline ring
through a linker as potential inhibitors of PDE4. Their design
was validated initially in silico by performing docking studies
using a representative molecule along with its two individual
fragments. The combined form showed better results than
the individual fragments. Subsequent synthesis of a focused
library of related hybrid molecules was accomplished using a
3-step method, the Pd/CACu mediated coupling-cyclization
being the key step. A range of compounds was synthesized
in good yields some of which showed PDE4 inhibition
in vitro and one of them appeared to be promising. Overall,
this research would be a new addition to the rapidly growing
area of bioactive hybrid molecules.
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